Nuvig Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 2
1 (50.0%)Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Nuvig Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT07095127
- Locations
- 🇺🇸
Nuvig Site, Westbury, New York, United States
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Phase 2
Recruiting
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Nuvig Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT07027111
- Locations
- 🇺🇸
Nuvig Site, Denton, Texas, United States
News
No news found